Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Dec;31(6):1290-1305.
doi: 10.1002/jgc4.1604. Epub 2022 Jul 7.

The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy-A systematic review and meta-analysis

Allison L Cirino  1   2 , Stephanie L Harris  3 , Andrea M Murad  4 , Brittany Hansen  5 , Jennifer Malinowski  6 , Jaime L Natoli  7 , Melissa A Kelly  8 , Susan Christian  9
Affiliations
Free article
Meta-Analysis

The uptake and utility of genetic testing and genetic counseling for hypertrophic cardiomyopathy-A systematic review and meta-analysis

Allison L Cirino et al. J Genet Couns. 2022 Dec.
Free article

Abstract

Genetic testing and genetic counseling are routinely indicated for patients with hypertrophic cardiomyopathy (HCM); however, the uptake and utility of these services is not entirely understood. This systematic review and meta-analysis summarizes the uptake and utility of genetic counseling and genetic testing for patients with HCM and their at-risk family members, as well as the impact of genetic counseling/testing on patient-reported outcomes (PROs). A systematic search was performed through March 12, 2021. Meta-analyses were performed whenever possible; other findings were qualitatively summarized. Forty-eight studies met inclusion criteria (47 observational, 1 randomized). Uptake of genetic testing in probands was 57% (95% confidence interval [CI]: 40, 73). Uptake of cascade screening for at-risk relatives were as follows: 61% for cascade genetic testing (95% CI: 45, 75), 58% for cardiac screening (e.g. echocardiography) (95% CI: 40, 73), and 69% for either/both approaches (95% CI: 43, 87). In addition, relatives of probands with a positive genetic test result were significantly more likely to undergo cascade screening compared to relatives of probands with a negative result (odds ratio = 3.17, 95% CI: 2.12, 4.76). Overall, uptake of genetic counseling in both probands and relatives ranged from 37% to 84%. Multiple studies found little difference in PROs between individuals receiving positive versus negative genetic test results; however, other studies found that individuals with positive genetic test results experienced worse psychological outcomes. Genetic testing may also inform life choices, particularly decisions related to reproduction and insurance. Genetic counseling was associated with high satisfaction, increased perceived personal control and empowerment, and decreased anxiety. Approximately half to three-quarters of patients with HCM and their relatives undergo genetic testing or cascade screening. PROs after genetic testing varied and genetic counseling was associated with high satisfaction and improved PROs.

Keywords: cascade testing; genetic counseling; genetic testing; hypertrophic cardiomyopathy; predictive genetic testing; systematic review; utility.

PubMed Disclaimer

References

REFERENCES

    1. Ahmad, F., McNally, E. M., Ackerman, M. J., Baty, L. C., Day, S. M., Kullo, I. J., Madueme, P. C., Maron, M. S., Martinez, M. W., Salberg, L., Taylor, M. R., & Wilcox, J. E. (2019). Establishment of specialized clinical cardiovascular genetics programs: Recognizing the need and meeting standards: A scientific statement from the American Heart Association. Circulation. Genomic and Precision Medicine, 12(6), e000054. https://doi.org/10.1161/HCG.0000000000000054
    1. Alashi, A., Svensson, L., Klein, J., Zahka, K., Smedira, N. G., Najm, H., Lever, H. M., Aziz, P., & Desai, M. Y. (2021). Characteristics and longer-term outcomes of contemporary patients <18 years of age with hypertrophic cardiomyopathy. The American Journal of Cardiology, 140, 110-117. https://doi.org/10.1016/j.amjcard.2020.10.060
    1. Alejandra Restrepo-Cordoba, M., Campuzano, O., Ripoll-Vera, T., Cobo-Marcos, M., Mademont-Soler, I., Gamez, J. M., Dominguez, F., Gonzalez-Lopez, E., Padron-Barthe, L., Lara-Pezzi, E., Alonso-Pulpon, L., Brugada, R., & Garcia-Pavia, P. (2017). Usefulness of genetic testing in hypertrophic cardiomyopathy: An analysis using real-world data. Journal of Cardiovascular Translational Research, 10(1), 35-46. https://doi.org/10.1007/s12265-017-9730-8
    1. Alfares, A. A., Kelly, M. A., McDermott, G., Funke, B. H., Lebo, M. S., Baxter, S. B., Shen, J., McLaughlin, H. M., Clark, E. H., Babb, L. J., Cox, S. W., DePalma, S. R., Ho, C. Y., Seidman, J. G., Seidman, C. E., & Rehm, H. L. (2015). Results of clinical genetic testing of 2,912 probands with hypertrophic cardiomyopathy: Expanded panels offer limited additional sensitivity. Genetics in Medicine, 17(11), 880-888. https://doi.org/10.1038/gim.2014.205
    1. Balduzzi, S., Rücker, G., & Schwarzer, G. (2019). How to perform a meta-analysis with R: A practical tutorial. Evidence-Based Mental Health, 22, 153-160.

Publication types